Rockefeller Capital Management L.P. Buys 3,744 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Rockefeller Capital Management L.P. raised its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 85.5% in the 4th quarter, HoldingsChannel reports. The firm owned 8,124 shares of the biopharmaceutical company’s stock after acquiring an additional 3,744 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Alnylam Pharmaceuticals were worth $3,231,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. MV Capital Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. HM Payson & Co. bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $27,000. Ameriflex Group Inc. bought a new position in Alnylam Pharmaceuticals in the third quarter worth approximately $32,000. Finally, Golden State Wealth Management LLC grew its stake in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 36 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $291.37 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.06 and a current ratio of 3.13. The company has a market capitalization of $38.90 billion, a price-to-earnings ratio of 79.61 and a beta of 0.29. Alnylam Pharmaceuticals, Inc. has a 52-week low of $273.11 and a 52-week high of $495.55. The company has a 50-day simple moving average of $296.26 and a two-hundred day simple moving average of $331.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company’s quarterly revenue was up 96.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.44) EPS. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ALNY shares. Jefferies Financial Group restated a “hold” rating and set a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Citigroup started coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 target price on the stock. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. HC Wainwright restated a “buy” rating and set a $510.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, June 4th. Finally, Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $463.13.

Insiders Place Their Bets

In other news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,740 shares of company stock worth $2,420,214 over the last quarter. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.